What is the projected market valuation for the Gastritis Treatment Market in 2035?

The projected market valuation for the Gastritis Treatment Market in 2035 is expected to reach 0.561 USD Billion. Read More

What was the market valuation for the Gastritis Treatment Market in 2024?

The overall market valuation for the Gastritis Treatment Market was 0.14 USD Billion in 2024. Read More

What is the expected CAGR for the Gastritis Treatment Market from 2025 to 2035?

The expected CAGR for the Gastritis Treatment Market during the forecast period 2025 - 2035 is 13.45%. Read More

What are the primary segments of the Gastritis Treatment Market?

The primary segments of the Gastritis Treatment Market include Diagnosis, Treatment Type, Drug Distribution Channel, and End-User. Read More

How much was the valuation for the Endoscopy segment in 2024?

The valuation for the Endoscopy segment in 2024 was 0.05 USD Billion. Read More

What is the projected valuation for Acid-blocking medicines in 2035?

The projected valuation for Acid-blocking medicines in 2035 is anticipated to reach 0.2 USD Billion. Read More

What distribution channels are utilized in the Gastritis Treatment Market?

Distribution channels in the Gastritis Treatment Market include Retail Pharmacy, Online Pharmacy, and Hospital Pharmacy. Read More

What was the valuation for Hospital & Clinics as an end-user segment in 2024?

The valuation for the Hospital & Clinics end-user segment was 0.08 USD Billion in 2024. Read More

What is the expected growth trend for the Gastritis Treatment Market?

The Gastritis Treatment Market appears to be on a growth trend, with a projected increase in valuation from 0.14 USD Billion in 2024 to 0.561 USD Billion by 2035. Read More

Gastritis Treatment Market

Q: Which companies are considered key players in the Gastritis Treatment Market?

Key players in the Gastritis Treatment Market include Pfizer, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Takeda Pharmaceutical, Sanofi, AbbVie, and Mylan. Read More

ID: MRFR/Pharma/4769-HCR

90 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Gastritis Treatment Market Research Report Information By Diagnosis (Blood Test and Endoscopy), Treatment (Acid Blocking Medicines and Antibiotics), Drug Distribution Channel (Retail Pharmacy), and End-User (Hospitals and Clinics) - Forecast Till 2035

Gastritis Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)13.45%

2024 Market Size$ 0.14 Billion

2025 Market Size$ 0.16 Billion

2035 Market Size$ 0.56 Billion

Key Players

Pfizer

Novartis

Bristol-Myers Squibb

GlaxoSmithKline

AstraZeneca

Takeda Pharmaceutical

Trends

Rising Demand for Personalized Medicine
Integration of Digital Health Solutions
Focus on Preventive Care and Lifestyle Modifications

Opportunities

Rising Healthcare Expenditure
Increasing Prevalence of Gastritis
Advancements in Pharmaceutical Research

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Diagnosis (USD Billion)
  1. 4.1.1 Blood test
  2. 4.1.2 Endoscopy
  3. 4.1.3 X-ray of upper digestive system
  4. 4.1.4 Others
2. 4.2 Healthcare, BY Treatment type (USD Billion)
  1. 4.2.1 Acid-blocking medicines
  2. 4.2.2 Antibiotics
  3. 4.2.3 Antacids
  4. 4.2.4 Histamine Blockers
3. 4.3 Healthcare, BY Drug Distribution Channel (USD Billion)
  1. 4.3.1 Retail Pharmacy
  2. 4.3.2 Online Pharmacy
  3. 4.3.3 Hospital Pharmacy
4. 4.4 Healthcare, BY End-User (USD Billion)
  1. 4.4.1 Hospital & Clinics
  2. 4.4.2 Others
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda Pharmaceutical (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Mylan (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
6. 6.6 US MARKET ANALYSIS BY END-USER
7. 6.7 CANADA MARKET ANALYSIS BY DIAGNOSIS
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
10. 6.10 CANADA MARKET ANALYSIS BY END-USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DIAGNOSIS
13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
15. 6.15 GERMANY MARKET ANALYSIS BY END-USER
16. 6.16 UK MARKET ANALYSIS BY DIAGNOSIS
17. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE
18. 6.18 UK MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
19. 6.19 UK MARKET ANALYSIS BY END-USER
20. 6.20 FRANCE MARKET ANALYSIS BY DIAGNOSIS
21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
23. 6.23 FRANCE MARKET ANALYSIS BY END-USER
24. 6.24 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
27. 6.27 RUSSIA MARKET ANALYSIS BY END-USER
28. 6.28 ITALY MARKET ANALYSIS BY DIAGNOSIS
29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 ITALY MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
31. 6.31 ITALY MARKET ANALYSIS BY END-USER
32. 6.32 SPAIN MARKET ANALYSIS BY DIAGNOSIS
33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
35. 6.35 SPAIN MARKET ANALYSIS BY END-USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DIAGNOSIS
42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE
43. 6.43 CHINA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
44. 6.44 CHINA MARKET ANALYSIS BY END-USER
45. 6.45 INDIA MARKET ANALYSIS BY DIAGNOSIS
46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE
47. 6.47 INDIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
48. 6.48 INDIA MARKET ANALYSIS BY END-USER
49. 6.49 JAPAN MARKET ANALYSIS BY DIAGNOSIS
50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
52. 6.52 JAPAN MARKET ANALYSIS BY END-USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
60. 6.60 MALAYSIA MARKET ANALYSIS BY END-USER
61. 6.61 THAILAND MARKET ANALYSIS BY DIAGNOSIS
62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
64. 6.64 THAILAND MARKET ANALYSIS BY END-USER
65. 6.65 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
68. 6.68 INDONESIA MARKET ANALYSIS BY END-USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
72. 6.72 REST OF APAC MARKET ANALYSIS BY END-USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
77. 6.77 BRAZIL MARKET ANALYSIS BY END-USER
78. 6.78 MEXICO MARKET ANALYSIS BY DIAGNOSIS
79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
81. 6.81 MEXICO MARKET ANALYSIS BY END-USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
85. 6.85 ARGENTINA MARKET ANALYSIS BY END-USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
102. 6.102 REST OF MEA MARKET ANALYSIS BY END-USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DRUG DISTRIBUTION CHANNEL, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DRUG DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.3.4 BY END-USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.4.4 BY END-USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.5.4 BY END-USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.6.4 BY END-USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.7.4 BY END-USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.8.4 BY END-USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.9.4 BY END-USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.10.4 BY END-USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.11.4 BY END-USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.12.4 BY END-USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.13.4 BY END-USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.14.4 BY END-USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.15.4 BY END-USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.16.4 BY END-USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.17.4 BY END-USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.18.4 BY END-USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.19.4 BY END-USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.20.4 BY END-USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.21.4 BY END-USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.22.4 BY END-USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.23.4 BY END-USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.24.4 BY END-USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.25.4 BY END-USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.26.4 BY END-USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.27.4 BY END-USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.28.4 BY END-USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.29.4 BY END-USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DIAGNOSIS, 2025-2035 (USD Billion)
  2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  4. 7.30.4 BY END-USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Gastritis Treatment Market Segmentation

Gastritis Treatment Market By Diagnosis (USD Billion, 2025-2035)

Blood test
Endoscopy
X-ray of upper digestive system
Others

Gastritis Treatment Market By Treatment type (USD Billion, 2025-2035)

Acid-blocking medicines
Antibiotics
Antacids
Histamine Blockers

Gastritis Treatment Market By Drug Distribution Channel (USD Billion, 2025-2035)

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy

Gastritis Treatment Market By End-User (USD Billion, 2025-2035)

Hospital & Clinics
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”